Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1642 1645 1649 1651 1674 1675 1677 1678
This examiner grants 64% of resolved cases
Examiner Adam M Weidner is assigned to Art Unit 1642 within Tech Center 1600, having overseen a total of 649 resolved cases. The available data shows an allowance rate of 63.5 percent for these applications. For those cases that result in a patent, the median days to allowance is 864. This timeframe serves as a data point for practitioners to evaluate the length of the prosecution process under this examiner's review.
The impact of examiner interviews is reflected in an interview lift of 33.8 percent. This metric illustrates the difference in the likelihood of allowance when an interview is conducted compared to the overall allowance rate of 63.5 percent. By examining the 649 resolved cases, practitioners can assess how direct engagement influences outcomes. Furthermore, the 864 median days to allowance helps in managing the prosecution timeline for applications assigned to Art Unit 1642 of Tech Center 1600.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18691254 | CD33 x Vd2 MULTISPECIFIC ANTIBODIES FOR THE TREATMENT OF CANCER | Non-Final OA | Janssen Biotech, Inc. |
| 17623913 | ANTIBODY DRUG CONJUGATE PURIFICATION | Non-Final OA | Merck Patent GmbH |
| 18528645 | SYSTEMS AND METHODS FOR THE PREPARATION OF PEPTIDE-MHC-I COMPLEXES WITH NATIVE GLYCAN MODIFICATIONS | Non-Final OA | The Regents of The University of California |
| 18230480 | COMPOSITIONS AND METHODS FOR TREATING BRAIN INJURY | Final Rejection | The Regents of the University of California |
| 17799444 | PLATELET FACTORS AND COGNITIVE IMPROVEMENT | Non-Final OA | The Regents of the University of California |
| 18581931 | AUTOIMMUNE ANTIBODIES FOR USE IN INHIBITING CANCER CELL GROWTH | Non-Final OA | The Johns Hopkins University |
| 18549803 | ANTI-AMYLOID BETA ANTIBODIES AND USES THEREOF | Non-Final OA | Eli Lilly and Company |
| 18487767 | COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING AUTOIMMUNE INDUCED CARDIAC LONG QT SYNDROME | Final Rejection | New York University |
| 18021085 | IGFBP7 FOR THE ASSESSMENT OF SILENT BRAIN INFARCTS AND COGNITIVE DECLINE | Non-Final OA | Roche Diagnostics Operations, Inc. |
| 18331607 | Targeted Gene Therapies for Pain and Other Neuro-Related Disorders | Final Rejection | University of Pittsburgh - Of the Commonwealth System of Higher Education |
| 18023573 | IMMUNOGENIC COMPOSITION TARGETING PHOSPHORYLATED TAU PROTEIN | Non-Final OA | OSAKA UNIVERSITY |
| 18562868 | Combination Therapies for Treating Cancer | Non-Final OA | GlaxoSmithKline Intellectual Property Development Limited |
| 18445651 | Fusion Protein Composition(s) Comprising Masked Type I Interferons (IFNa and IFNb) For Use in the Treatment of Cancer and Methods Thereof | Non-Final OA | Nammi Therapeutics, Inc. |
| 18579591 | USE OF INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 2 IN THE PREPARATION OF DRUGS FOR THE TREATMENT OF NEUROLOGICAL DEMYELINATING DISEASES | Non-Final OA | SHANGHAI MENTAL HEALTH CENTER (SHANGHAI PSYCHOLOGICAL COUNSELLING TRAINING CENTER) |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy